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Serum snoRNAs as biomarkers for 
joint ageing and post traumatic 
osteoarthritis
Mandy M. F. Steinbusch1, Yongxiang Fang2, Peter I. Milner3, Peter D. Clegg3, David A. Young4, 
Tim J. M. Welting1 & Mandy J. Peffers3
The development of effective treatments for the age-related disease osteoarthritis and the ability 
to predict disease progression has been hampered by the lack of biomarkers able to demonstrate 
the course of the disease. Profiling the expression patterns of small nucleolar RNAs (snoRNAs) 
in joint ageing and OA may provide diagnostic biomarkers and therapeutic targets. This study 
determined expression patterns of snoRNAs in joint ageing and OA and examined them as potential 
biomarkers. Using SnoRNASeq and real-time quantitative PCR (qRT-PCR) we demonstrate snoRNA 
expression levels in murine ageing and OA joints and serum for the first time. SnoRNASeq identified 
differential expression (DE) of 6 snoRNAs in young versus old joints and 5 snoRNAs in old sham versus 
old experimental osteoarthritic joints. In serum we found differential presence of 27 snoRNAs in 
young versus old serum and 18 snoRNAs in old sham versus old experimental osteoarthritic serum. 
Confirmatory qRT-PCR analysis demonstrated good correlation with SnoRNASeq findings. Profiling the 
expression patterns of snoRNAs is the initial step in determining their functional significance in ageing 
and osteoarthritis, and provides potential diagnostic biomarkers and therapeutic targets. Our results 
establish snoRNAs as novel markers of musculoskeletal ageing and osteoarthritis.
Osteoarthritis (OA) is an age-related musculoskeletal disease and a common cause of chronic disability world-
wide1. In addition it is a significant contributor to both individual and socioeconomic burden and the number of 
disability adapted life years globally2. If the deterioration in musculoskeletal health and development of OA can 
be identified and treated early serious life impairment may be abrogated. Ageing is the time-dependent reduction 
of functional capacity and stress resistance, associated with an increased risk of morbidity and mortality. The 
joint and its articular cartilage is particularly affected by ageing3. There is evidence that the rate of ageing, that 
is the ‘biological age’, differs significantly between individuals’ actual age in years (i.e. the ‘chronological age’). 
Defining markers of joint ageing may enable a prediction of the risk of onset of OA, enabling early intervention. 
OA is characterised by a non-symptomatic, pre-radiographical phase that if identified would allow earlier diag-
nosis. However radiographic changes are only evident later in disease progression. Magnetic resonance imaging 
techniques have been developed for early-stage evaluation of cartilage damage in OA but are expensive and con-
traindicated in some individuals.
The development of effective treatments for OA and the ability to predict disease progression has been ham-
pered by the lack of substantive biomarkers, able to demonstrate pathological disturbances preceding identifiable 
tissue alterations. Others have attempted to identify products of tissue turnover in serum and synovial fluid 
(reviewed4). This has been challenging due to patient and disease heterogeneity and dilution effects either by 
tissue fluids or with similar products from other joints or diseases. In addition, the variability of antibody assays 
has been problematic.
SnoRNAs are a class of evolutionary conserved non-coding small guide RNAs of which the majority direct the 
chemical modification of other RNA substrates, including ribosomal RNAs and spliceosomal RNAs. In addition, 
some snoRNAs are involved in the regulation of alternative splicing and post-transcriptional modification of 
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mRNA, whilst others exhibit miR-like activity5. Aberrant expression of snoRNAs has been associated with disease 
development5 such as lung tumorigenesis6.
Emerging evidence shows that there is an increased level of circulating RNAs in the serum of cancer patients7. 
Circulating microRNAs (miRs) have been extensively described as biomarkers for diseases like pancreatic/breast 
cancer8,9, Alzheimer’s disease10 and inflammatory diseases like asthma, inflammatory bowel disease and rheu-
matoid arthiritis11, but with the recent discovery of stable12 snoRNAs in serum, interest in their potential as 
circulating biomarkers of cancers (reviewed5) has been stimulated. We have previously identified dysregulation 
of a defined set of snoRNAs in cartilage13 and tendon14 ageing and OA15 and in man, snoRNA SNORD38 and 
SNORD48 were identified as potential non-age-dependant serum biomarkers for OA progression following cru-
ciate ligament injury12.
Expression profiling of snoRNAs in ageing and OA may help in determining their functional significance in 
the development and progression of disease and provide much needed diagnostic biomarkers for ageing and OA 
development. This study compared serum and joint snoRNA expression in ageing and OA from knee joint tissues 
from young and old adult mice and old mice using a traumatic in vivo model of OA. Because OA involves the 
whole joint as an organ; we undertook our analysis on whole mouse joints, which included cartilage, meniscus, 
subchondral bone, and joint capsule with synovium.
Materials and Methods
All reagents were from Thermo-Fisher-Scientific, unless stated.
Animals. C57BL6/J male mice were used for the study. For SnoRNASeq old mice were 18 months old (n = 6), 
young 8 months old (n = 6)16 and mice used for destabilisation of the medial meniscus (DMM) 24 months old 
(sham n = 3; DMM n = 6). Mice were group housed in individually ventilated cages at a 12 hour light/dark cycle, 
with ad libitum access to food and water. Experimental animal protocols were performed in accordance with the 
guidelines of the Animals (Scientific Procedures) Act 1986 following ethical review. Animal usage and protocols 
for this study was approved by the University of Liverpool Animal Welfare Committee.
Surgical induction of OA by DMM in mice. DMM surgery was perform as previously reported17. Briefly, 
under anaesthesia a 3 mm skin incision was made over the medial aspect of the patellar ligament through the joint 
capsule into the femorotibial joint of the left knee. The medial meniscotibial ligament was transected to destabilise 
the cranial pole of the medial meniscus from the anterior tibial plateau. In sham operated mice the medial menis-
cotibial ligament was visualised but not transected. Mice were sacrificed 8 weeks post-surgery.
Joint and serum collection for SnoRNASeq. Following euthanasia, knee joints were collected from 
young, old, DMM (n = 6 each group) and sham n = 3 for SnoRNASeq. Joints were harvested free of soft tissues at 
7 mm from the joint into RNALater. Serum was collected using cardiac puncture. One old serum sample was not 
processed further due to extensive haemolysis.
OARSI scoring of histological sections of mouse knee joints. For histology, as the total knee joint 
was used in the study for RNA extraction, joints were collected (into 4% paraformaldehyde) from additional 
equivalent aged and treated young (n = 8), old (n = 4); sham (n = 5); and DMM (n = 6) mice in order to eval-
uate the extent of OA. The procedure, surgeon and duration of the studies were identical. Knees were decalci-
fied in 0.5 M ethylenediaminetetraacetic acid (pH 7.4) for 4 weeks at 4 °C and coronally embedded in paraffin. 
Sectioning, Safranin-O Fast-Green staining and histological scoring (defined as the severity and extent of OA) 
was undertaken on a scale from 1 to 6 by two blinded independent observers using the OARSI histopathology 
initiative18. All four quadrants of the section (medial tibial plateau, lateral tibial plateau, medial femoral condyle, 
lateral femoral condyle) were scored individually and added for each histological section. For statistical analyses 
mean summed score values of joints of 3–5 section per knee joint at 4 depths throughout the joint was determined 
(thus a maximum score of 24 was possible). Inter-observer variability was calculated using Cohen’s Kappa statis-
tics using an online software tool: (http://www.statstodo.com/CohenKappa).
RNA isolation, RNA-Seq analysis, cDNA library preparation and sequencing. Total RNA was 
isolated from equal weights of joints and 500 μ l serum using miRNeasy or RNeasy Serum kits respectively with 
DNase treatment (all Qiagen, Crawley, UK) to remove residual gDNA. Total RNA integrity (RIN) was confirmed 
using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, USA). Ribosomal RNA was depleted 
using the Ribo-Zero™ rRNA Removal Kit (Epicentre, Madison, USA). From 41 samples 100 ng of rRNA-depleted 
RNA was submitted for library preparation using NEB small RNA library kit (New England Biolabs (NEB), 
Ipswich, USA). To reduce workflow bias we used tobacco acid pyrophosphatase (Epicentre, Madison, USA) to 
remove potential 5′ caps found on some snoRNAs. Samples were amplified for 15 cycles, mixed into 3 pools, 
and size selected. The size-selected material was purified with Ampure beads (Agencourt, Beckman-Coulter, 
High-Wycombe, UK). SnoRNA sequencing was undertaken on the Illumina HiSeq 2000 platform (Illumina, San 
Diego, USA) using 100 base paired-end reads.
SnoRNASeq data analysis. Sequence data measured from 5 lanes of an Illumina HiSeq2000 were pro-
cessed through a number of steps to obtain snoRNA expression values. The processes include basecalling and 
de-multiplexing of indexed reads using CASAVA version 1.8.219; adapter and quality trimming using Cutadapt 
version 1.2.120 and Sickle version 1.200 to obtain fastq files of trimmed reads; aligning reads to Ensembl 
GRCm38.77 mouse genome reference sequences which contains 1,555 annotated snoRNA features using 
Bowtie221 version 2.0.10 with option “–very-sensitive-local”; counting aligned reads against snoRNA features 
using THSeq-count. The count values were used as snoRNA expression measurements for the DE analysis.
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DE analysis was performed in R environment using package edgeR22. The processes and technical details 
of the analysis include: assessing data variation and detecting outlier samples through comparing variations of 
within and between sample groups using principle component analysis (PCA; 3-D PCA plots were generated 
using R function in package plot3D) and correlation analysis; handling library size variation respectively for joint 
samples and serum samples through data normalisation; formulating data variation using negative binomial 
distributions; modelling data using a generalised linear model; computing log2 Fold Change (logFC) values for 
required contrasts based on model fitting results through contrast fitting approach, assigning P-values to logFC 
values by LR23 testing; dealing with the effects of multiple tests using FDR approach to obtain FDR adjusted 
P-values; and defining significantly DE snoRNAs as those with FDR-adjusted p-value < 5%. Sequence data have 
been submitted to National Centre for Biotechnology Information Gene Expression Omnibus (NCBI GEO); 
E-MTAB-4878.
RNA isolation, poly(A) cDNA synthesis and snoRNA qRT-PCR. qRT-PCR of snoRNAs was 
performed24. Total RNA was isolated using the mirVana kit. Isolated RNA samples were polyadenylated at 37 °C 
for 60 minutes in a 50 μ L reaction volume containing 1 μ g RNA and 1.5 U poly(A) polymerase (NEB, Ipswich, 
USA). 500 μ L lysis binding buffer was added. Then, an equal volume of acid-phenol:chloroform was added, vor-
texed and samples were centrifuged for 10 minutes and the aqueous phase removed. The poly(A)-tailed total 
RNA was extracted using the filter cartridge provided by the mirVana kit. To generate poly(A) cDNA, 500 ng 
poly(A)-tailed RNA and 250 ng RTQ primer (Eurogentec, Seraing, Belgium) (Table 1) were mixed in a 26 μ L reac-
tion volume, incubated at 65 °C for 10 minutes and annealed at 4 °C for 20 minutes. Reverse transcription was per-
formed with 200 U M-MLV reverse transcriptase, 20 U RNAsin (both Promega, Southampton, UK), 2 μ L dNTP 
mix (10 mM each; Eurogentec, Seraing, Belgium) and 8 μ L 5x M-MLV buffer (Promega, Sothampton, USA) in 
a total reaction volume of 40 μ L at 50 °C for 60 minutes. The reverse transcriptase was inactivated at 70 °C for 
15 minutes. Finally, 1.5 U of RNAse H (NEB, Ipswich, USA) was added to remove small RNAs. A snoRNA-specific 
forward primer and a universal reverse primer (RTQ-UNIr, matched to the Tm of each individual snoRNA) 
were used for the amplification of each snoRNA target (all Eurogentec, Seraing, Belgium) (Table 1). For each 
cDNA sample a mix was prepared with Mesagreen qPCR Mastermix Plus for SYBR Green (Eurogentec, Seraing, 
Belgium) and 300 nM forward and reverse oligonucleotides. An ABI-7300 Detection System was used for ampli-
fication using the following protocol: denaturation at 95 °C for 5 minutes, followed by 50 cycles of DNA ampli-
fication (15 seconds 95 °C and 45 seconds annealing at 62–68 °C). The annealing temperature was optimized for 
each snoRNAs target. Serially diluted standard curves were utilized to quantify snoRNA expression and data was 
normalized to a validated housekeeping snoRNA (joint: U2, young-old serum: SNORD85, old sham-old DMM 
serum and equine serum: U6).
Validation of SNORD116 as a marker of OA in equine serum. We determined the reproducibility of 
the expression of SNORD116 in OA serum of another species. There are well-published studies on the application 
of metacarpophalangeal (MCP) joint OA changes in the horse, a joint with similarities to the human knee joint25. 
We studied equine serum from normal and MCP OA horses collected from eight normal (mean age ± standard 
deviation 5.3 ± 2.1 years) and four OA (7.5 ± 1.0 years) castrated male thoroughbred horses at post-mortem. 
Samples were collected under the regulations of the Hong Kong Jockey Club with owner consent and stored at 
− 80 °C. OA diagnosis was based on histological (modified Mankin)26 and synovitis scoring27 of MCP joint tissues.
Name Sequence (5′-3′) Tm (°C)
RTQ primer poly(A) cDNA synthesis
CGAATTCTAGAGCTCGAGGCAGGC 
GACATGGCTGGCTAGTTAAGCTTG 
GTACCGAGCTCGGATCCACTAGTCC 
TTTTTTTTTTTTTTTTTTTTTTTTTVN
75
Snora28 CATGAGACAAGCCGTTATATAGGC 50
Snora30 TGTACCAGTGGCAGCTGTTACTC 50
Snora31 CTTTGTGGCAGTTCAGATTGAATTAG 50
Snora64 GTGGCCTCTCTTGCCTAGAG 65
Snora73 ACAGTGACTGAGGAGGCAAAC 50
Snord46 AATGCAAGGACTTGTCATAGTTACAC 50
Snord85 TTAGACCAGAGGTCGATGATGAG 50
Snord88 ACCTTTGACACCTGGAGATCTGA 50
Snord116 TGTACCGCCACTCTCATCGG 65
U2 TGGTATTGCAGTACCTCCAGGAACG 55
U3 AGTGAGAGGGAGAGAACGCGGTC 55
U6 GATGACACGCAAATTCGTGAAGCGTTC 55
RTQ-UNIr-50 AATTCTAGAGCTCGAGGCAGG 50
RTQ-UNIr-55 CGAATTCTAGAGCTCGAGGCAGG 55
RTQ-UNIr-65 CTAGAGCTCGAGGCAGGCGACATGGCTGGC 65
Table 1.  Oligonucleotides sequences used in qRT-PCR.
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Statistical analysis. For statistical evaluation of histological scoring non-parametric Mann-Whitney-U test 
was used. Inter-observer agreement of histological scoring systems was calculated using Cohen’s kappa coefficient 
(www.statstodo.com/CohenKappa_Pgm.phpl). qRT-PCR data was log-transformed prior to statistical evaluation 
with an independent samples t-test. Statistical evaluation was performed between young and old or old sham 
versus old DMM using GraphPad Prism 5 (San Diego); p-values are indicated.
Results
OARSI scoring of joints. OARSI scoring of joints (mean ± 95%CI) for young and old were 0.5 ± 0.3 and 
2.8 ± 2.7 (p = 0.01), and old sham and old DMM were 1.25 ± 1.1 and 6.5 ± 0.7 (p < 0.001), respectively. Mice 
exhibited typical histological features of OA in the DMM knees. Cohen’s Kappa statistic was 0.4 indicating a fair 
agreement. Representative histological images and OARSI scoring are in Fig. 1.
Preliminary analysis SnoRNASeq. To identify DE of snoRNAs in mouse joints and serum in response 
to age and OA 41 cDNA libraries representing old and young joints (old = HJO; young = HJY) and serum 
(old = HSO; young = HSY), and old sham and old DMM joints and serum (sham joint = DJC, DMM joint = DJM, 
sham serum = DSC and DMM serum = DSM) were constructed and subjected to Illumina deep sequencing. 
Summaries of raw, trimmed reads and sequencing alignment to mouse snoRNAs are in Supplementary files 1 
and 2 respectively. Reads mapping percentages for joint libraries were between 12~29%, and for serum libraries 
0.03~0.9%. Between 42~53% of the 1555 mouse snoRNA reference sequences were aligned for joints and 16~26% 
for serum.
Identification of DE snoRNAs using SnoRNASeq. The 3-D PCA plot (Fig. 2A) shows that the joint 
samples and serum samples are clearly separated by the 1st component, which explains 93.02% of the data var-
iation. For serum samples, the group sham and the group DMM scatter separately on the 2nd component, fur-
thermore, based on the 3rd component a clear separation between serum samples of young-healthy and samples 
of old-healthy exists. For joint samples, there is also a separation between DMM and sham samples, though the 
separation is not as clear as shown for serum samples. In addition, 5 DMM joint samples scatter far away from 
other joint samples on the 3rd component. Therefore, it can be expected that disease response small RNA can be 
detected from this data set. The heat map of hierarchical clusters of correlations among samples (Fig. 2B) depicts 
that the joint and serum groups of samples are very different in snoRNA expression. In addition, joint samples 
correlated to each other much more closely than serum samples confirming the phenomena revealed by the PCA 
analysis shown in Fig. 2A. This indicates that major disease responses in the data were contributed from serum 
samples. A read length distribution graph was generated to highlight the constitutional difference of non-coding 
RNAs in joint and serum samples at 100 bp or below (Fig. 2C). For this one serum and one joint sample with 
approximately the same library size were chosen. The plots of the read length distribution for joint and serum 
Figure 1. Histological changes of in the mouse knee showing the medial femoral condyle (above) and 
medial tibial plateau (below). (A) Safranin O with Fast-Green counterstain. Scale bar, 100 μ m. Red indicates 
proteoglycan. (B/C) Assessment of osteoarthritis development was evaluated by OARSI scores; young (n = 8) 
vs. old (n = 4) (B); sham (n = 5) vs. DMM (n = 6) (C). Data represents the mean + 95% confidence interval (CI) 
for each scorer. For statistical evaluation an independent samples t-test was performed using GraphPad Prism 5 
(San Diego); p-values are indicated.
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samples reveal that a peak value of frequency for read length in joint samples is 22 bp (vertical, dotted black line). 
Therefore the corresponding reads are generally well annotated miRNAs. Another peak is noted at around 100 bp, 
which is consistent with non-coding RNAs whose length is a hundred bp and over. In contrast, a peak is presented 
at 30 bp long for serum samples (vertical, dotted red line). More than 50% of the reads are 30 bp long in the serum 
library (data not shown). In contrast, the joint library has just 1.14% of reads that are 30 bp long (data not shown). 
Such reads may come from piwi-interacting RNAs (piRNAs). There were 498–646 snoRNAs expressed in serum 
samples and 1068–1286 in joint samples. The DE snoRNAs between contrasts are in Table 2. These included 6 
snoRNAs in young versus old joints, 5 snoRNAs in old sham versus old DMM joints. In serum we identified DE 
of 27 snoRNAs in young versus old serum and 18 snoRNAs in old sham versus old DMM serum.
Validation of SnoRNASeq data using qRT-PCR. Very little is known about the roles of snoRNAs as 
biomarker for disease or about the functional roles of snoRNAs in mammalian cell biology. We thus could not 
define functional criteria to select snoRNAs for validation based on prior knowledge. To stay unbiased we thus 
selected snoRNAs from the RNAseq data that displayed a moderate fold significant expression difference, higher 
fold significant expression difference, non-significant expression difference and selected box H/ACA (SNORAs) 
as well as box C/D (SNORDs) snoRNAs for validation. Levels of candidate snoRNAs for further qRT-qPCR 
analysis were determined using the original RNA from all donors used to perform the SnoRNASeq experiment. 
There was good concordance between SnoRNASeq and qRT-PCR platforms (Table 2 and Fig. 3). SNORD88 
Figure 2. Variation data between the expressions for 41 samples. (A) A 3-D PCA plot of the first three 
components from principal component analysis of logarithm-transformed small RNA abundance data. 
Variance (%) associated with each principle component is depicted on the respective axis. Abbreviations; 
Joint: young healthy (HJY; black), old healthy (HJO; red), old sham (DJC; magenta), old DMM (DJM; light 
blue). Serum: young healthy (HSY; green), old healthy (HSO; dark blue), old sham (DSC; grey), old DMM 
(DSM; yellow). (B) The heat map of hierarchical clusters of correlations among samples. Pearson’s correlation 
coefficients were computed using logarithm transformed small RNA expression data from all known snoRNAs 
that were detected. (C) The plots of read length distribution for two representative joint and serum samples.
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Contrast Gene ID Name Log2 FC FDR Host Gene
Young vs. Old joint
ENSMUSG00000098372 SNORD113 − 0.92 0.05 Predicted gene
ENSMUSG00000065016 SNORA3 − 0.80 0.01 Ribosomal protein L27A
ENSMUSG00000080352 SNORD88 − 0.55 0.00 RIKEN cDNA 2410002F23 gene
ENSMUSG00000064380 SNORA73 0.56 0.03 Ribosomal protein SA
ENSMUSG00000087883 SNORA17 1.21 0.05 Contactin associated protein-like 5B
ENSMUSG00000064536 SNORD38 1.49 0.05 PDZ domain containing 4
Young vs. Old serum
ENSMUSG00000089255 SNORA78 − 2.29 0.01 Ribosomal protein S2
ENSMUSG00000080396 SNORD111 − 1.38 0.01 Splicing factor 3b, subunit 3
ENSMUSG00000065883 U3 − 2.53 0.00 Predicted gene
ENSMUSG00000064500 SNORD95 1.16 0.01 Guanine nucleotide binding protein, beta polypeptide 2 like 1
ENSMUSG00000095118 SNORD14D 1.23 0.00 Heat shock protein 8
ENSMUSG00000065219 SNORD32A 1.55 0.04 Ribosomal protein L13A
ENSMUSG00000088678 SNORA17 1.90 0.03 Predicted gene
ENSMUSG00000064938 miR3068/SNORA58 1.96 0.00 AlkB, alkylation repair homolog 1
ENSMUSG00000065282 SNORA18 1.99 0.00 Predicted gene
ENSMUSG00000064387 SNORA73A 2.02 0.01 Regulator of chromosome condensation 1
ENSMUSG00000064602 SNORA41 2.12 0.00 Eukaryotic translation elongation factor 1 beta 2
ENSMUSG00000088670 SNORA31 2.14 0.03 Regulatory associated protein of MTOR, complex 1
ENSMUSG00000064918 SNORD18 2.18 0.02 Ribosomal protein L4
ENSMUSG00000065158 SNORA73 2.26 0.02 ERO1-like beta
ENSMUSG00000064493 SNORA28 2.39 0.03 Eukaryotic translation initiation factor 5
ENSMUSG00000077167 SNORA53 2.43 0.00 Solute carrier family 25
ENSMUSG00000064495 SNORA5 2.49 0.00 Transforming growth factor beta regulated gene 4
ENSMUSG00000064569 SNORD71 2.56 0.00 Adaptor-related protein complex 1, gamma 1 subunit
ENSMUSG00000064791 SNORD14E 2.63 0.00 Heat shock protein 8
ENSMUSG00000077714 SNORD17 2.76 0.00 Sorting nexin 5
ENSMUSG00000065353 SNORD73B 2.79 0.00 Regulator of chromosome condensation 1 and an lnc
ENSMUSG00000064696 SNORD20 3.09 0.00 Nucleolin
ENSMUSG00000065778 SNORA55 3.10 0.02 Poly(A) binding protein, cytoplasmic 4
ENSMUSG00000080478 SNORD23 4.42 0.00 Glioma tumor suppressor candidate region gene 2
ENSMUSG00000095176 SNORA44 5.65 0.00 Hypothetical protein PNAS-123
ENSMUSG00000088040 SNORA17 12.14 0.00 Hypothetical protein MGC16037, homology human collagen alpha 2
ENSMUSG00000065852 SNORA2 13.40 0.00 Hypothetical protein, 152aa
Sham vs. DMM joint
ENSMUSG00000064655 SNORA55 − 0.88 0.04 Poly(A) binding protein, cytoplasmic 4
ENSMUSG00000098971 SNORD113 − 0.99 0.04 Lnc-NA imprinted and accumulated in nucleus
ENSMUSG00000064858 SNORA43 − 1.12 0.04 Lnc- small nucleolar RNA host gene 7
ENSMUSG00000065105 SNORA29 − 1.22 0.04 T-complex protein 1
ENSMUSG00000077191 SNORA64 − 1.62 0.04 Small nuclear ribonucleoprotein N
Sham vs. DMM serum
ENSMUSG00000096017 SNORD116 10.56 0.01 Predicted gene
ENSMUSG00000064938 miR3068 3.31 0.03 AlkB, alkylation repair homolog 1
ENSMUSG00000089014 SNORA36 3.05 0.01 Dyskerin
ENSMUSG00000077222 SNORA66 2.78 0.05 Ribosomal protein L5
ENSMUSG00000064918 SNORD18 2.21 0.01 Ribosomal protein L4
ENSMUSG00000064400 U3 1.92 0.01 Predicted gene
ENSMUSG00000089417 U90 1.90 0.01 Importin
ENSMUSG00000077709 SNORA64 1.85 0.04 Small nuclear ribonucleoprotein N
ENSMUSG00000065734 SNORD49A − 1.03 0.05 RIKEN cDNA 2410006H16 gene
ENSMUSG00000064450 SNORD68 − 1.06 0.04 Ribosomal protein L13
ENSMUSG00000064844 SNORD58 − 1.18 0.01 Ribosomal protein L17
ENSMUSG00000064453 SNORD21 − 1.22 0.01 Ribosomal protein L5
ENSMUSG00000065281 SNORD27 − 1.31 0.01 Small nucleolar RNA host gene 1
ENSMUSG00000064871 SNORD58B − 1.40 0.05 Ribosomal protein L17
ENSMUSG00000087819 SNORA48 − 1.41 0.04 Nucleosome assembly protein 1-like 1
ENSMUSG00000064751 SNORD46 − 1.46 0.01 Ribosomal protein S8
ENSMUSG00000077756 SNORD90 − 1.48 0.01 Ring finger and CCCH-type zinc finger domains 2
ENSMUSG00000089093 SNORD11 − 1.86 0.03 NOP58 ribonucleoprotein
Table 2.  Differentially expressed snoRNAs between contrasts including host gene identification. 
Explanation: positive Log2 FC = increased in old or DMM. Negative Log2 FC = is decreased in old or DMM.
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was significantly decreased in young versus old joint (Fig. 3A), while SNORA73 was validated to be increased 
in young versus old joint (Fig. 3A). In agreement with its absence in the DE group (Table 2), SNORA30 was not 
differentially expressed in young versus old joint (Fig. 3A) and SNORD88 was not differentially expressed in sham 
versus DMM joint (Fig. 3A). SNORA31, SNORA28, SNORD23 and SNORA73 were confirmed to be significantly 
increased in young versus old serum (Fig. 3B) and SNORD116, SNORA64 and U3 were significantly increased 
in sham versus DMM serum (Fig. 3C). SNORD46 was confirmed to be significantly decreased in DMM serum as 
compared to sham serum (Fig. 3C).
SNORD116 in equine serum in OA. To confirm increased SNORD116 in OA serum levels in a differ-
ent species using qRT-PCR, we measured SNORD116 in equine serum samples. Normal equine donors had a 
Mankin’s score 1.25 ± 0.9 (mean ± 95%CI) and OA donors 7.75 ± 7.6. Synovial membrane from normal donors 
had a synovitis score27 of 3.25 ± 2.3 and OA donors 3.25 ± 3.2. There was a significant increase in serum expres-
sion of SNORD116 in OA compared to normal donors (p = 0.0010) (Fig. 4).
Discussion
SnoRNAs are emerging as important regulators of cell functions, such as alternative splicing28, metabolic stress29 
and development of disease; in cancer6, Prader-Willi Syndrome and autism5. Through expression profiling of 
snoRNAs using deep-sequencing we reveal novel molecular features relating to joint ageing and OA.
Whilst gene expression has been evaluated in animal models of OA, including the rat anterior cruciate transection30 
and meniscal tear models31, and mouse DMM model32 these were primarily interrogating protein-coding genes. 
Furthermore, apart from the final study these experiments evaluated a single tissue, primarily articular cartilage. 
In musculoskeletal ageing single tissues have been investigated13,14. OA is a process that involves the whole joint 
as an organ; therefore we undertook our analysis on whole mouse joints, which included cartilage, meniscus, 
subchondral bone, and joint capsule with synovium.
Mice are considered skeletally mature at around 3-months-old (approximate equivalent of a teenaged human) 
while a 12-month-old mouse would signify a 40 to 50 year human33. Thus, to investigate the effects of joint age 
we used 8-month-old equivalent to 25 to 28 year human (referred to as young) and 24-month-old mice (referred 
to as old). To study the development of post-traumatic OA we measured OA severity histologically and analysed 
snoRNAs expression in joints and serum from 24-month-old mice following DMM. Limitations of this study 
were that we did not additionally undertake the DMM model in young mice. Additionally the ‘old’ age in young 
versus old contrast was not the same age as ‘old’ age in sham versus DMM. OARSI scores that were observed in 
the sham group (DMM surgery cohort; 24 months old) were lower than the old group (young versus old cohort; 
18 months old). At this moment we cannot explain this difference, but different housing and environments of the 
two cohorts may have influenced this. The DMM model is a post-injury model in which the histological lesions 
within the affected joint are similar to those observed in human OA17. Mild OA-like pathology was present in 
the old and sham mice implying that mice at this age are in the early stages of acquiring naturally occurring OA 
comparable to studies of human knees at the equivalent age of approximately 40 years-old34. However the effect 
of the DMM model exacerbated these changes.
Detection of snoRNAs in serum has previously been demonstrated12,35,36. SnoRNAs are serum stable, and 
although normally resident in the nucleolus it is thought in serum they are present as unidentified protein com-
plexes12. It is however not clear whether disease-associated RNAs detected in the circulation result from local 
tissue disturbances and cell death, or whether they are actively locally secreted via exosomes or microvesicles or 
are a systemic response upon local tissue damage8,37,38. This may even depend on the specific pathology or spe-
cific RNA species. Determining the average read-length distribution of representative joint and serum samples 
(Fig. 2C) revealed an unexpected finding. When looking at the read-length distribution the serum reads spe-
cifically contain a large peak of RNAs with a length of approximately 30 nt. The combined realisation that quite 
a large portion of the reads could not be mapped back to the used genome database, that a large portion of the 
piRNA class of non-coding RNAs lacks annotation in the used genome database and that piRNAs are typically 
30 nt long, makes it is reasonable to think that this explains the presence of the large 30 nt peak specifically in 
serum. Only recently the presence of piRNAs in human blood has been described39 and this significant difference 
in the constitution of small RNAs for joint and serum samples is a phenomenon calling for further investigation.
In the young versus old serum (27 snoRNAs) more snoRNAs were significantly up-regulated compared to 
the old sham versus old DMM serum (18 snoRNAs) indicating ageing per se had a greater effect on differential 
snoRNA presence in serum than OA. This could be due to different ‘old’ ages in the comparisons, but also maybe 
expected as in ageing serum snoRNAs will be from many tissues whereas in the DMM model we are most likely 
highlighting primarily OA joint-related snoRNAs. As we were studying the whole joint this may be due to vary-
ing expression of snoRNAs in joint tissues, as it is known that there is tissue-specific snoRNAs expression40. We 
are unable to determine the amount each tissue type contributed to overall expression of snoRNAs. Each tissue 
will vary in its cellularity and hence RNA and snoRNAs content. Thus whilst a novel aspect of this study was 
that snoRNAs were extracted from the multiple tissues that form the joint, our approach may be less sensitive 
in detecting snoRNAs that change in a single tissue. However it has the advantage of determining snoRNAs that 
could be more globally implicated in OA. Despite the potential limitations, we identified a number of potentially 
interesting snoRNAs for future studies.
SNORA73 was increased in old joint and serum (Table 2, Fig. 3) and represents a potential joint ‘biological 
ageing’ marker. A reliable measurement of the state of ageing and a prediction of the risk of the onset of morbid-
ity for chronic age-related diseases such as OA would be beneficial. Such a strategy could serve as a measure of 
‘biological’ age and predict an age-related biological response more accurately than chronological age. SNORA64 
was increased and SNORD46 was decreased in DMM serum, but both were not DE in young versus old serum, 
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indicating these snoRNAs as possible OA markers. SNORD18 was increased in serum both in ageing and follow-
ing DMM (Table 2) signifying that they are affected in ageing and also OA. It is difficult to speculate how much 
this snoRNA changes in age-related OA versus age from this study. Histology identified mild increase in OARSI 
score with age and the level of OA changes in the DMM model was mild. It would be beneficial to investigate this 
snoRNAs further in tissues and serum in more severe OA.
An interesting finding was an increase in SNORD38 in ageing joint. Zhang et al.12 demonstrated a strong 
association between serum levels of SNORD38 and severe cartilage damage, in anterior cruciate ligament (ACL) 
injury, enabling distinction between ACL injury patients from normal donors. They were unable to determine 
Figure 3. SnoRNA expression from SnoRNASeq was validated with qRT-PCR. (A) Gene expression patterns 
of SNORD88, SNORA73 and SNORA30 were confirmed in young and old joint. SNORD88 expression was 
verified in sham and DMM joint. (B) SNORA31, SNORA28, SNORD23 and SNORA73 were confirmed to 
be increased in old serum. (C) Gene expression patterns of SNORD116, SNORA64, U3 and SNORD46 were 
validated in sham and DMM serum. Gene expression is depicted as fold induction relative to control (i.e. young 
or sham). Data represents the mean + 95% CI. For statistical evaluation an independent samples t-test was 
performed using GraphPad Prism 5 (San Diego) on log-transformed data; p-values are indicated.
Figure 4. Increased gene expression of SNORD116 in equine OA serum as compared to serum from 
normal donors. Data represents the mean + 95% CI. For statistical evaluation an independent samples t-test 
was performed using GraphPad Prism 5 (San Diego) on log-transformed data; p = 0.0010.
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age effect of SNORD38 in serum from normal donors as it was undetectable. One year post-surgery there was 
no relationship between donor age and serum SNORD38. Our study demonstrated an increase in SNORD38 in 
mouse joints (but not serum) with age. The human study did not assess tissue snoRNAs and the serum samples 
were primarily from middle-aged donors. Our old mice group represents an equivalent older age than that in the 
human study, which could contribute to this disparity.
The most DE snoRNA in DMM serum was SNORD116. Additionally we demonstrated an increase in serum 
SNORD116 in horses with MCP OA. We have previously identified SNORD116 as increased in OA compared 
to normal human cartilage in an array study15. A loss of SNORD116 is a significant contribution to the aetiology 
of the neurodegenerative genetic condition Prader-Willi syndrome (PWS)41. This paternally imprinted disor-
der results in developmental delay and genetic obesity due to hyperphagia42. Clinical signs include short stature 
and low bone mineral density43. In a recent mouse transgenic study the loss of PWS critical region (including 
SNORD116) resulted in reduced bone mineral density (BMD), delayed skeletal development and reduced bone 
size and osteoblastic suppression44. Humans with OA have an increased BMD in affected joints45. Thus our find-
ings not only elucidate a potential marker of OA but a snoRNA with a potential role in the pathogenesis of OA.
Previously we have identified DE snoRNAs in ageing cartilage13 and tendon14 and together with results in this 
study we propose that in musculoskeletal tissues snoRNAs potentially modulate the ageing process as previously 
described46. While determining the transcriptomic signature of ageing equine cartilage13 we found the differen-
tial expression of a number of snoRNAs associated with ageing. When comparing the differentially expressed 
snoRNAs between the equine and this mouse study it is important to realize that in our previous equine study we 
did not analyse serum or the whole joint, but specifically the articular cartilage. Overlapping differential snoRNA 
expression between studies was identified for SNORD113, SNORA53, SNORA48 and SNORA5. SNORA53 was 
decreased in old equine cartilage, but increased in old mouse serum. SNORA48 was decreased in old equine 
cartilage, and decreased in old DMM mouse serum. SNORA5 was increased in old equine cartilage and increased 
in old mouse serum. Possibly the best consistency was found for SNORD113, which was decreased in old mouse 
joint (and old DMM mouse joint) and equine cartilage. The apparent cross-species conservations of differentially 
expressed snoRNAs in ageing and OA strengthen our belief that snoRNAs could indeed be used as biomarkers. 
Further analysis of snoRNA expression profiles and detailed genetic studies will give new insights into novel 
molecular networks in musculoskeletal ageing and common mechanisms in ageing and age-related diseases such 
as OA.
In mammalians the majority of snoRNAs are encoded within the introns of protein coding or non-coding 
genes; host-genes47. There is evidence that genes which host snoRNAs might contribute to the aetiology of cancer 
through regulation of cell homeostasis and cancer biology (reviewed6). Potentially both the host-gene and the 
snoRNAs encoded within them may be important in different situations. For example growth-arrest-specific-5 
(GAS-5) (hosts ten C/D box snoRNAs48), a non-coding RNA which accumulates in growth arrested cells, reg-
ulates cell death and proliferation by acting as a decoy hormone response element for glucocorticoid receptors 
thereby inhibiting gene upregulation by activated glucocorticoid receptors49. Interesting snoRNA host-genes were 
identified in this study including transforming growth factor β regulated gene 4, sorting nexin 5 and collagen type 
1 (with roles in joint homeostasis). Therefore, an alteration of snoRNA expression may result from changes in 
transcriptional activity of the host-gene related to joint homeostasis or disease.
Conclusion
Our results implicate specific changes in snoRNA abundance in joint ageing (SNORD88 and SNORD38 were 
respectively decreased and increased) and OA suggesting the potential use of snoRNAs such as SNORA73 and 
SNORD23 as a novel biomarker for joint ageing, SNORA64, SNORD46 and SNORD116 for OA, SNORD18 for 
ageing and OA.
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